22 results
Approved WMOWill not start
To assess the pharmacokinetics and safety of naloxegol in paediatric patients ages > 6 months to < 18 years receiving treatment with opioids.
Approved WMORecruiting
The objective of this study is to evaluate the (cost-)effectiveness of reduced noradrenaline in patients with CS by using a lower MAP target of >= 55 mmHg, compared to usual care. We hypothesize that reduced use of noradrenaline will improve…